Novavax (NVAX) EBT (2010 - 2026)

Novavax's EBT history runs 17 years deep, the most recent figure standing at -$8.5 million for Q1 2026.

• In Q1 2026, EBT fell 101.64% year-over-year to -$8.5 million; the TTM figure through Mar 2026 stood at -$86.2 million (down 117.64% YoY), while the FY2025 annual figure was $442.2 million, up 350.36% from the prior year.
• EBT for Q1 2026 stood at -$8.5 million, down from $17.9 million in the prior quarter.
• The five-year high for EBT was $519.8 million in Q1 2025, with the low at -$509.1 million in Q2 2022.
• The 5-year median for EBT is -$122.3 million (2024), against an average of -$55.3 million.
• The sharpest annual moves came in 2023 and 2025: EBT slumped 242.05% in 2023, then surged 457.8% in 2025.
• Novavax's EBT stood at -$184.5 million in 2022, then gained by 4.23% to -$176.7 million in 2023, then surged by 58.36% to -$73.6 million in 2024, then surged by 124.33% to $17.9 million in 2025, then plunged by 147.51% to -$8.5 million in 2026.
• Business Quant data shows NVAX's EBT at -$8.5 million in Q1 2026, $17.9 million in Q4 2025, and -$203.0 million in Q3 2025.